Please Wait.....
Report
Vaccine Market Report by Technology (Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines, and Others), Patient Type (Pediatric, Adult), Indication (Bacterial Diseases, Viral Diseases), Route of Administration (Intramuscular and Subcutaneous Administration, Oral Administration, and Others), Product Type (Multivalent Vaccine, Monovalent Vaccine), Treatment Type (Preventive Vaccine, Therapeutic Vaccine), End User (Hospitals, Clinics, Vaccination Centers, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Institutional Sales, and Others), and Region 2025-2033
Market Report I 2025-04-01 I 144 Pages I IMARC Group
The global vaccine market size reached USD 59.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 136.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.12% during 2025-2033. The implementation of stringent regulations promoting the adoption of vaccination among individuals, several advances in biotechnology and vaccine development techniques, and the growing health awareness among the population about the importance of vaccination are some of the major factors propelling the market.
Vaccines are essential tools in public health, designed to prevent and control the spread of infectious diseases. They are essentially biological preparations that stimulate the immune system to recognize and fight specific pathogens, such as bacteria or viruses. They contain weakened or inactivated forms of the target pathogen or pieces of it, known as antigens. When administered, vaccination mimic an infection, prompting the immune system to produce antibodies and develop immune memory. Additionally, it ensures immune system to swiftly mount a defense, effectively preventing illness or reducing its severity, when the individual is exposed to the actual pathogen.
The market is primarily driven by the growing health concerns among individuals. In addition, the recent onset of the coronavirus disease (COVID-19) pandemic raised awareness among individuals regarding the importance of the product in safeguarding public health, thus augmenting the market growth. Moreover, the development of novel vaccine technologies, such as mRNA products are transforming the industry by offering faster and precise vaccine development capabilities, addressing emerging threats effectively, thus representing another major growth-inducing factor. Besides this, pharmaceutical companies are expanding their vaccine portfolios to include vaccinations for various diseases beyond the traditional ones which opened new markets and revenue streams, thus accelerating the sales demand. Along with this, several government initiatives including vaccination drives, public awareness campaigns, and funding for vaccine research to curb the spread of diseases are propelling the market growth. Furthermore, the ongoing vaccine research and development investment (R&D) in public and private sectors ensures a robust pipeline of new products, thus creating a positive market outlook.
Vaccine Market Trends/Drivers:
The implementation of stringent regulations promoting the adoption of vaccination
The market is driven by the enforcement of stringent regulations aimed at promoting vaccination among individuals. In addition, the growing emphasis on vaccine safety and efficacy is augmenting the market growth. Moreover, manufacturers adhere to rigorous testing and quality control measures to ensure that products meet the highest standards of safety, resulting in rising investment in research and development (R&D) to create products that prevent diseases effectively and have minimal adverse effects, thus representing another major growth-inducing factor. Besides this, companies are providing clear and comprehensive information about their products, including potential side effects and contraindications which empowers individuals to make informed decisions about vaccination, thus accelerating the product adoption rate. Along with this, various governments and healthcare authorities are implementing various incentive programs including subsidies, public awareness campaigns, and mandates in some cases encouraging the adoption of vaccination, thus propelling the market growth.
Several advances in biotechnology and vaccine development techniques
The market is driven by several remarkable advances in biotechnology and vaccine development techniques. It is transforming the way vaccinations are designed and manufactured which is contributing to the development of highly effective and targeted vaccinations. In addition, the utilization of genomics and molecular biology in vaccine development led scientists to decode the genetic information of pathogens with unprecedented speed and precision, enabling them to identify potential vaccine candidates more efficiently, resulting in the development of products against emerging diseases such as COVID-19, thus augmenting the market growth. Moreover, several advancements in recombinant deoxyribonucleic acid (DNA) technology allowed for the creation of recombinant vaccinations, stimulating enhanced immune response without causing the disease itself which is effective in preventing infectious diseases, including hepatitis B and human papillomavirus, thus representing another major growth-induing factor. Furthermore, the application of synthetic biology techniques is also contributing to several innovations, allowing scientists to design and synthesize vaccine components with precision, for the development of novel vaccinations against challenging pathogens, thus creating a positive market outlook.
The growing awareness about the importance of vaccination
The market is driven by the growing health awareness among individuals regarding the importance of vaccination. In addition, the recent onset of the coronavirus disease (COVID-19) pandemic raised public awareness about the value of vaccination, thus augmenting the market growth. Along with this, manufacturers are developing and distributing vaccinations to combat the virus while focusing on vaccine efficacy, safety, and accessibility, thus propelling the market growth. Moreover, the dissemination of accurate information through various channels, including healthcare providers, government agencies, and the media to safeguard public health, which represents another major growth-inducing factor. Besides this, the rise of social media and digital platforms played a significant part in providing information about vaccinations, enabling individuals to access reliable resources and engage in informed discussions.
Vaccine Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global vaccine market report, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on technology, patient type, indication, route of administration, product type, treatment type, end user, and distribution channel.
Breakup by Technology:
- Conjugate Vaccines
- Inactivated and Subunit Vaccines
- Live Attenuated Vaccines
- Recombinant Vaccines
- Toxoid Vaccines
- Others
The report has provided a detailed breakup and analysis of the market based on technology. This includes conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, toxoid vaccines, and others.
Conjugate products are gaining popularity due to their effectiveness in preventing bacterial infections. They are designed to elicit a strong immune response and are particularly used for diseases such as haemophilus influenzae type B (Hib) and streptococcus pneumoniae.
Moreover, inactivated and subunit products are widely used for viral diseases, such as influenza, hepatitis B, and human papillomavirus (HPV) which contain components of the pathogen, ensuring safety while still providing immunity, thus representing another major growth-inducing factor. Besides this, Live attenuated vaccines are created from weakened forms of pathogens and are effective against diseases such as measles, mumps, and rubella which are essential in disease eradication programs, thus accelerating the sales demand.
Along with this, recombinant products use genetic engineering to create vaccinations against diseases such as hepatitis B and human papillomavirus and offer potential for customization and efficacy, thus propelling the market growth. Also, toxoid vaccinations are employed for bacterial diseases including diphtheria and tetanus due to their long-lasting immunity benefits, thus augmenting the market growth.
Breakup by Patient Type:
- Pediatric
- Adult
Pediatric patients hold the largest share of the market
A detailed breakup and analysis of the market based on the patient type has also been provided in the report. This includes pediatric and adult. According to the report, pediatrics accounted for the largest market share.
The pediatrics segment is driven by the growing emphasis on immunization, thus influencing the market growth. Moreover, governments and healthcare organizations are preventing childhood diseases, leading to increasing vaccination programs and investments in pediatric vaccine research, thus contributing to market growth.
Moreover, several advancements in vaccine technology made it possible to develop safer and more effective vaccinations for children, resulting in a steady stream of new vaccinations tailored specifically for pediatric populations, representing another major growth-inducing factor.
Additionally, the COVID-19 pandemic underscored the importance of vaccinations for children. Efforts to vaccinate children against the virus further increase the role of pediatrics in the vaccine industry, thus propelling the market growth.
Breakup by Indication:
- Bacterial Diseases
o Meningococcal Disease
o Pneumococcal Disease
o Diphtheria/Tetanus/Pertussis (DPT)
o Tuberculosis
o Haemophilus Influenzae (Hib)
o Typhoid
o Others
- Viral Diseases
o Hepatitis
o Influenza
o Human Papillomavirus (HPV)
o Measles/Mumps/Rubella (MMR)
o Rotavirus
o Herpes Zoster
o Varicella
o Japanese Encephalitis
o Rubella
o Polio
o Rabies
o Dengue
o Others
Bacterial diseases presently account for the largest market share
A detailed breakup and analysis of the market based on the indication has also been provided in the report. This includes bacterial diseases (meningococcal disease, pneumococcal disease, diphtheria/tetanus/pertussis (DPT), tuberculosis, haemophilus influenza (Hib), typhoid, and others) and viral diseases (hepatitis, influenzae, human papillomavirus (HPV), measles/mumps/rubella (MMR), rotavirus, herpes zoster, varicella, Japanese encephalitis, rubella, polio, rabies, dengue, and others). According to the report, bacterial diseases accounted for the largest market share.
The market is driven by the growing incidences of bacterial diseases, caused by various bacteria such as Streptococcus pneumoniae and Haemophilus influenzae. In addition, the increasing development of effective vaccinations to prevent these infections is augmenting the market growth.
Furthermore, several advancements in vaccine technology are improving bacterial disease vaccinations. Along with this, several innovations in research and development (R&D) yielded vaccinations that are effective and safe for widespread use which are designed to stimulate the body's immune response, thereby conferring immunity against bacterial pathogens, thus propelling the market growth.
Breakup by Route of Administration:
- Intramuscular and Subcutaneous Administration
- Oral Administration
- Others
Intramuscular and subcutaneous administration represents the leading segment
The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes intramuscular and subcutaneous administration, oral administration, and others. According to the report, intramuscular and subcutaneous administration accounted for the largest market share.
Intramuscular administration involves injecting vaccinations directly into the muscle tissue which offers several advantages. In addition, muscles have an abundant blood supply, allowing for efficient uptake and distribution of the vaccine components leading to improved immune response, thus influencing the market growth. Along with this, IM injections often require larger needles, which can facilitate the administration of vaccinations with thicker formulations or those containing adjuvants, thus augmenting the market growth.
Moreover, subcutaneous administration involves injecting vaccinations into the fatty tissue just beneath the skin which is preferred for products that are well-suited for slower, sustained release into the bloodstream, thus representing another major growth-inducing factor. It is less invasive and typically uses smaller needles, making it a preferred choice among individuals who may be apprehensive about needles.
Breakup by Product Type:
- Multivalent Vaccine
- Monovalent Vaccine
Multivalent vaccine represent the most used product type
The report has provided a detailed breakup and analysis of the market based on the product type. This includes multivalent vaccine and monovalent vaccine. According to the report, multivalent vaccine accounted for the largest market share.
Multivalent offers a streamlined approach to immunization by combining antigens from different pathogens into a single vaccine, which reduces the number of injections required, minimizing discomfort for patients and simplifying vaccination schedules, thus augmenting the market growth.
Furthermore, multivalent vaccinations are efficient in preventing several diseases. For instance, combination vaccinations such as the measles, mumps, and rubella (MMR) vaccinations are eliminating these diseases in many regions, resulting in extensive research and development (R&D) efforts in the field, thus propelling the market growth.
Along with this, multivalent vaccinations offer substantial advantages, as the production, distribution, and administration of a single vaccine covering multiple diseases are more efficient and economical compared to individual vaccinations for each pathogen, thus accelerating the product adoption rate among healthcare systems and patients.
Breakup by Treatment Type:
- Preventive Vaccine
- Therapeutic Vaccine
Preventive vaccine currently dominates the market
The report has provided a detailed breakup and analysis of the market based on the treatment type. This includes preventive vaccine and therapeutic vaccine. According to the report, preventive vaccine accounted for the largest market share.
Preventive vaccinations are designed to proactively protect individuals from contracting specific diseases. They achieve this by stimulating the immune system to produce antibodies that recognize and neutralize pathogens, such as viruses or bacteria, should the individual be exposed to them in the future has proven to be highly effective in reducing the incidence and severity of various illnesses.
Moreover, it has immense success in eradicating or controlling life-threatening diseases. Some historical examples include the near-eradication of smallpox through vaccination and the significant reduction in polio cases which are essential in fighting against infectious diseases. Furthermore, the rapid development and distribution of products to combat the virus and save countless lives are propelling the market growth.
Breakup by End User:
- Hospitals
- Clinics
- Vaccination Centers
- Academic and Research Institutes
- Others
Hospitals hold the largest share of the market
A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals, clinics, vaccination centers, academic and research institutes, and others. According to the report, hospitals accounted for the largest market share.
The hospital industry is driven by its strategic position as a primary healthcare provider. In addition, hospitals serve as the frontline of defense against infectious diseases, making them the ideal setting for vaccine dissemination which possesses the necessary infrastructure, medical personnel, and resources to efficiently handle the storage, distribution, and administration of products, thus propelling the market growth.
Furthermore, hospitals are essential in vaccination advocacy and education. They are trusted sources of healthcare information, and their healthcare professionals serve as product advocates through patient consultations, seminars, and informational campaigns. Along with this, hospitals are promoting the importance of vaccination, contributing to higher vaccination rates and public awareness.
Along with this, hospitals also engage in product research and development (R&D), partnering with pharmaceutical companies and research institutions to conduct clinical trials and assess vaccination efficacy, thus contributing to market growth.
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Institutional Sales
- Others
Hospital pharmacies presently account for the largest market share
A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, institutional sales, and others. According to the report, hospital pharmacies accounted for the largest market share.
Hospital pharmacies are located at the heart of healthcare facilities which ensures that vaccinations are easily accessible to healthcare professionals and patients. Hospitals are often the first point of contact for individuals seeking vaccination, whether it's for routine immunizations or during public health emergencies.
Moreover, hospital pharmacies have the infrastructure and trained staff necessary to handle and administer products safely while adhering to strict quality control and storage protocols, ensuring the integrity and efficacy of vaccinations throughout the distribution process, thus representing another major growth-inducing factor. This reliability and commitment to maintaining the cold chain are essential for preserving the potency of products.
Along with this, hospital pharmacies benefit from established relationships with healthcare providers and government agencies responsible for vaccination programs which allows for seamless coordination in vaccination procurement, distribution, and administration, thus propelling the market growth. Also, hospitals serve as vaccination hubs during mass immunization campaigns, further solidifying their role in the market.
Breakup by Region:
- North America
o United States
o Canada
- Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Russia
o Others
- Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Others
- Latin America
o Brazil
o Mexico
o Others
- Middle East and Africa
o Turkey
o GCC Countries
o Israel
o Others
Asia Pacific exhibits a clear dominance in the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific accounted for the largest market share.
The Asia Pacific market is driven by the growing pharmaceutical and biotechnology sector. In addition, several countries such as India and China are investing heavily in the development of their healthcare infrastructure, research capabilities, and manufacturing capacities, allowing them to produce vaccination at scale, often at a lower cost than their Western counterparts. thus, contributing to the market growth.
Additionally, the rising pool of skilled scientists, researchers, and healthcare professionals is augmenting the market growth. These experts are driving innovation and ensuring the quality and safety of vaccinations produced in the region. Furthermore, the region offers ample opportunities for clinical trials and testing, allowing for the accelerated development of new products, thus accelerating the sales demand.
Apart from this, the strategic partnerships and collaborations among pharmaceutical companies in the region are facilitating technology transfer, knowledge sharing, and access to critical resources, strengthening the region's position in the market.
Competitive Landscape:
At present, key players in the market are taking strategic initiatives to strengthen their positions in the competitive landscape of the market research and consulting services industry. These actions are vital for maintaining their relevance and authority in the field. They are embracing advanced technologies including artificial intelligence, machine learning, and data analytics which help in delivering more accurate and actionable insights, that is highly valued by clients. Moreover, companies are establishing thought leadership through content marketing and thought-provoking research reports which help in showcasing expertise and attract clients who seek industry insights. Besides this, they are focusing on client satisfaction and building long-term relationships by providing personalized services and tailored solutions based on client requirements that enhance trust and loyalty.
The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
- Abbott Laboratories
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bharat Biotech International
- Bavarian Nordic A/S
- CSL Limited
- Daiichi Sankyo Company Limited
- Emergent BioSolutions Inc.
- GlaxoSmithKline Plc
- Inovio Pharmaceuticals Inc.
- Johnson & Johnson
- Merck & Co. Inc.
- Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
- Novavax Inc.
- Panacea Biotec Ltd.
- Pfizer Inc.
- Sanofi Pasteur SA (Sanofi SA)
- Serum Institute of India Pvt. Ltd.
- Takeda Pharmaceutical Company Limited.
Recent Developments:
- In September 2020, the Serum Institute of India Pvt. Ltd., partnered with Gavi and the Bill & Melinda Gates Foundation to accelerate the production and distribution of an additional 100 million doses of COVID-19 vaccines that are safe and effective.
- In April 2023, Pfizer Inc., announced data from phase 3 trials of its RSV shots. The trial conducted in adult patients demonstrated that the shot was 67% more effective in preventing infections with two related symptoms and 86% effective in case of severe disease. The successful approval of this vaccine will make it the first product in the RSV market.
- In June 2022, GlaxoSmithKline Plc officially submitted a Biologics License Application (BLA) to the United States Food and Drug Administration (USFDA) for their experimental vaccine known as PRIORIX, which originally registered in Germany, has received licenses from more than 100 countries.
Key Questions Answered in This Report
1.What was the size of the global vaccine market in 2024?
2.What is the expected growth rate of the global vaccine market during 2025-2033?
3.What are the key factors driving the global vaccine market?
4.What has been the impact of COVID-19 on the global vaccine market?
5.What is the breakup of the global vaccine market based on the patient type?
6.What is the breakup of the global vaccine market based on the indication?
7.What is the breakup of the global vaccine market based on the route of administration?
8.What is the breakup of the global vaccine market based on the product type?
9.What is the breakup of the global vaccine market based on the treatment type?
10.What is the breakup of the global vaccine market based on the end user?
11.What is the breakup of the global vaccine market based on the distribution channel?
12.What are the key regions in the global vaccine market?
13.Who are the key players/companies in the global vaccine market?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
4.2.1 Regulatory Landscape
4.2.1.1 United States
4.2.1.2 Canada
4.2.1.3 European Union
4.2.1.4 China
4.2.1.5 India
4.2.1.6 Japan
4.2.1.7 South Korea
4.2.1.8 Australia
4.2.1.9 Russia
4.2.1.10 Brazil
4.2.1.11 Mexico
4.2.1.12 Turkey
4.2.1.13 GCC Countries
4.2.1.14 Israel
4.2.2 Product Pipeline for New Vaccines
4.2.2.1 Product Pipeline for HIV
4.2.2.2 Product Pipeline for Zika Virus
4.2.2.3 Product Pipeline for Ebola Virus
4.2.2.4 Product Pipeline for COVID-19
5 Global Vaccine Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Technology
6.1 Conjugate Vaccines
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Inactivated and Subunit Vaccines
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Live Attenuated Vaccines
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Recombinant Vaccines
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Toxoid Vaccines
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 Market Breakup by Patient Type
7.1 Paediatric
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Adult
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Indication
8.1 Bacterial Diseases
8.1.1 Market Trends
8.1.2 Major Types
8.1.2.1 Meningococcal Disease
8.1.2.1.1 Market Trends
8.1.2.1.2 Market Forecast
8.1.2.2 Pneumococcal Disease
8.1.2.2.1 Market Trends
8.1.2.2.2 Market Forecast
8.1.2.3 Diphtheria/Tetanus/Pertussis (DPT)
8.1.2.3.1 Market Trends
8.1.2.3.2 Market Forecast
8.1.2.4 Tuberculosis
8.1.2.4.1 Market Trends
8.1.2.4.2 Market Forecast
8.1.2.5 Haemophilus Influenzae (Hib)
8.1.2.5.1 Market Trends
8.1.2.5.2 Market Forecast
8.1.2.6 Typhoid
8.1.2.6.1 Market Trends
8.1.2.6.2 Market Forecast
8.1.2.7 Others
8.1.2.7.1 Market Trends
8.1.2.7.2 Market Forecast
8.1.3 Market Forecast
8.2 Viral Diseases
8.2.1 Market Trends
8.2.2 Major Types
8.2.2.1 Hepatitis
8.2.2.1.1 Market Trends
8.2.2.1.2 Market Forecast
8.2.2.2 Influenza
8.2.2.2.1 Market Trends
8.2.2.2.2 Market Forecast
8.2.2.3 Human Papillomavirus (HPV)
8.2.2.3.1 Market Trends
8.2.2.3.2 Market Forecast
8.2.2.4 Measles/Mumps/Rubella (MMR)
8.2.2.4.1 Market Trends
8.2.2.4.2 Market Forecast
8.2.2.5 Rotavirus
8.2.2.5.1 Market Trends
8.2.2.5.2 Market Forecast
8.2.2.6 Herpes Zoster
8.2.2.6.1 Market Trends
8.2.2.6.2 Market Forecast
8.2.2.7 Varicella
8.2.2.7.1 Market Trends
8.2.2.7.2 Market Forecast
8.2.2.8 Japanese Encephalitis
8.2.2.8.1 Market Trends
8.2.2.8.2 Market Forecast
8.2.2.9 Rubella
8.2.2.9.1 Market Trends
8.2.2.9.2 Market Forecast
8.2.2.10 Polio
8.2.2.10.1 Market Trends
8.2.2.10.2 Market Forecast
8.2.2.11 Rabies
8.2.2.11.1 Market Trends
8.2.2.11.2 Market Forecast
8.2.2.12 Dengue
8.2.2.12.1 Market Trends
8.2.2.12.2 Market Forecast
8.2.2.13 Others
8.2.2.13.1 Market Trends
8.2.2.13.2 Market Forecast
8.2.3 Market Forecast
9 Market Breakup by Route of Administration
9.1 Intramuscular and Subcutaneous Administration
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Oral Administration
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Others
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Product Type
10.1 Multivalent Vaccine
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Monovalent Vaccine
10.2.1 Market Trends
10.2.2 Market Forecast
11 Market Breakup by Treatment Type
11.1 Preventive Vaccine
11.1.1 Market Trends
11.1.2 Market Forecast
11.2 Therapeutic Vaccine
11.2.1 Market Trends
11.2.2 Market Forecast
12 Market Breakup by End User
12.1 Hospitals
12.1.1 Market Trends
12.1.2 Market Forecast
12.2 Clinics
12.2.1 Market Trends
12.2.2 Market Forecast
12.3 Vaccination Centres
12.3.1 Market Trends
12.3.2 Market Forecast
12.4 Academic and Research Institutes
12.4.1 Market Trends
12.4.2 Market Forecast
12.5 Others
12.5.1 Market Trends
12.5.2 Market Forecast
13 Market Breakup by Distribution Channel
13.1 Hospital Pharmacies
13.1.1 Market Trends
13.1.2 Market Forecast
13.2 Retail Pharmacies
13.2.1 Market Trends
13.2.2 Market Forecast
13.3 Institutional Sales
13.3.1 Market Trends
13.3.2 Market Forecast
13.4 Others
13.4.1 Market Trends
13.4.2 Market Forecast
14 Market Breakup by Region
14.1 North America
14.1.1 United States
14.1.1.1 Market Trends
14.1.1.2 Market Forecast
14.1.2 Canada
14.1.2.1 Market Trends
14.1.2.2 Market Forecast
14.2 Asia Pacific
14.2.1 China
14.2.1.1 Market Trends
14.2.1.2 Market Forecast
14.2.2 Japan
14.2.2.1 Market Trends
14.2.2.2 Market Forecast
14.2.3 India
14.2.3.1 Market Trends
14.2.3.2 Market Forecast
14.2.4 South Korea
14.2.4.1 Market Trends
14.2.4.2 Market Forecast
14.2.5 Australia
14.2.5.1 Market Trends
14.2.5.2 Market Forecast
14.2.6 Others
14.2.6.1 Market Trends
14.2.6.2 Market Forecast
14.3 Europe
14.3.1 Germany
14.3.1.1 Market Trends
14.3.1.2 Market Forecast
14.3.2 France
14.3.2.1 Market Trends
14.3.2.2 Market Forecast
14.3.3 United Kingdom
14.3.3.1 Market Trends
14.3.3.2 Market Forecast
14.3.4 Italy
14.3.4.1 Market Trends
14.3.4.2 Market Forecast
14.3.5 Spain
14.3.5.1 Market Trends
14.3.5.2 Market Forecast
14.3.6 Russia
14.3.6.1 Market Trends
14.3.6.2 Market Forecast
14.3.7 Others
14.3.7.1 Market Trends
14.3.7.2 Market Forecast
14.4 Latin America
14.4.1 Brazil
14.4.1.1 Market Trends
14.4.1.2 Market Forecast
14.4.2 Mexico
14.4.2.1 Market Trends
14.4.2.2 Market Forecast
14.4.3 Others
14.4.3.1 Market Trends
14.4.3.2 Market Forecast
14.5 Middle East and Africa
14.5.1 Turkey
14.5.1.1 Market Trends
14.5.1.2 Market Forecast
14.5.2 GCC Countries
14.5.2.1 Market Trends
14.5.2.2 Market Forecast
14.5.3 Israel
14.5.3.1 Market Trends
14.5.3.2 Market Forecast
14.5.4 Others
14.5.4.1 Market Trends
14.5.4.2 Market Forecast
15 SWOT Analysis
15.1 Overview
15.2 Strengths
15.3 Weaknesses
15.4 Opportunities
15.5 Threats
16 Value Chain Analysis
16.1 Exploratory Stage
16.2 Preclinical and Clinical Development
16.3 Regulatory Approval
16.4 Manufacturing
16.5 Marketing and Distribution
17 Porters Five Forces Analysis
17.1 Overview
17.2 Bargaining Power of Buyers
17.3 Bargaining Power of Suppliers
17.4 Degree of Competition
17.5 Threat of New Entrants
17.6 Threat of Substitutes
18 Price Analysis
19 Major Drivers and Challenges
20 Competitive Landscape
20.1 Market Structure
20.2 Key Players
20.3 Profiles of Key Players
20.3.1 Abbott Laboratories
20.3.1.1 Company Overview
20.3.1.2 Product Portfolio
20.3.1.3 Financials
20.3.1.4 SWOT Analysis
20.3.2 Astellas Pharma Inc.
20.3.2.1 Company Overview
20.3.2.2 Product Portfolio
20.3.2.3 Financials
20.3.2.4 SWOT Analysis
20.3.3 AstraZeneca Plc
20.3.3.1 Company Overview
20.3.3.2 Product Portfolio
20.3.3.3 Financials
20.3.3.4 SWOT Analysis
20.3.4 Bharat Biotech International
20.3.4.1 Company Overview
20.3.4.2 Product Portfolio
20.3.5 Bavarian Nordic A/S
20.3.5.1 Company Overview
20.3.5.2 Product Portfolio
20.3.5.3 Financials
20.3.6 CSL Limited
20.3.6.1 Company Overview
20.3.6.2 Product Portfolio
20.3.6.3 Financials
20.3.6.4 SWOT Analysis
20.3.7 Daiichi Sankyo Company Limited
20.3.7.1 Company Overview
20.3.7.2 Product Portfolio
20.3.8 Emergent BioSolutions Inc.
20.3.8.1 Company Overview
20.3.8.2 Product Portfolio
20.3.8.3 Financials
20.3.8.4 SWOT Analysis
20.3.9 GlaxoSmithKline Plc
20.3.9.1 Company Overview
20.3.9.2 Product Portfolio
20.3.9.3 Financials
20.3.9.4 SWOT Analysis
20.3.10 Inovio Pharmaceuticals Inc.
20.3.10.1 Company Overview
20.3.10.2 Product Portfolio
20.3.10.3 Financials
20.3.10.4 SWOT Analysis
20.3.11 Johnson & Johnson
20.3.11.1 Company Overview
20.3.11.2 Product Portfolio
20.3.11.3 Financials
20.3.11.4 SWOT Analysis
20.3.12 Merck & Co. Inc.
20.3.12.1 Company Overview
20.3.12.2 Product Portfolio
20.3.12.3 Financials
20.3.12.4 SWOT Analysis
20.3.13 Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
20.3.13.1 Company Overview
20.3.13.2 Product Portfolio
20.3.13.3 Financials
20.3.13.4 SWOT Analysis
20.3.14 Novavax Inc.
20.3.14.1 Company Overview
20.3.14.2 Product Portfolio
20.3.14.3 Financials
20.3.14.4 SWOT Analysis
20.3.15 Panacea Biotec Ltd.
20.3.15.1 Company Overview
20.3.15.2 Product Portfolio
20.3.16 Pfizer Inc.
20.3.16.1 Company Overview
20.3.16.2 Product Portfolio
20.3.16.3 Financials
20.3.16.4 SWOT Analysis
20.3.17 Sanofi Pasteur SA (Sanofi SA)
20.3.17.1 Company Overview
20.3.17.2 Product Portfolio
20.3.17.3 Financials
20.3.17.4 SWOT Analysis
20.3.18 Serum Institute of India Pvt. Ltd.
20.3.18.1 Company Overview
20.3.18.2 Product Portfolio
20.3.19 Takeda Pharmaceutical Company Limited
20.3.19.1 Company Overview
20.3.19.2 Product Portfolio
20.3.19.3 Financials
20.3.19.4 SWOT Analysis
Figure 1: Global: Vaccine Market: Major Drivers and Challenges
Figure 2: Global: Vaccine Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Vaccine Market Forecast: Sales Value (in Billion ?????????????????????USD), 2025-2033
Figure 4: Global: Vaccine Market: Breakup by Technology (in %), 2024
Figure 5: Global: Vaccine Market: Breakup by Patient Type (in %), 2024
Figure 6: Global: Vaccine Market: Breakup by Indication (in %), 2024
Figure 7: Global: Vaccine Market: Breakup by Route of Administration (in %), 2024
Figure 8: Global: Vaccine Market: Breakup by Product Type (in %), 2024
Figure 9: Global: Vaccine Market: Breakup by Treatment Type (in %), 2024
Figure 10: Global: Vaccine Market: Breakup by End User (in %), 2024
Figure 11: Global: Vaccine Market: Breakup by Distribution Channel (in %), 2024
Figure 12: Global: Vaccine Market: Breakup by Region (in %), 2024
Figure 13: Global: Vaccine (Conjugate Vaccines) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 14: Global: Vaccine (Conjugate Vaccines) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 15: Global: Vaccine (Inactivated and Subunit Vaccines) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 16: Global: Vaccine (Inactivated and Subunit Vaccines) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 17: Global: Vaccine (Live Attenuated Vaccines) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 18: Global: Vaccine (Live Attenuated Vaccines) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 19: Global: Vaccine (Recombinant Vaccines) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 20: Global: Vaccine (Recombinant Vaccines) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 21: Global: Vaccine (Toxoid Vaccines) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 22: Global: Vaccine (Toxoid Vaccines) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 23: Global: Vaccine (Other Technologies) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 24: Global: Vaccine (Other Technologies) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 25: Global: Vaccine (Paediatric) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 26: Global: Vaccine (Paediatric) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 27: Global: Vaccine (Adult) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 28: Global: Vaccine (Adult) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 29: Global: Vaccine (Bacterial Diseases) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 30: Global: Vaccine (Bacterial Diseases) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 31: Global: Vaccine (Meningococcal Disease) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 32: Global: Vaccine (Meningococcal Disease) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 33: Global: Vaccine (Pneumococcal Disease) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 34: Global: Vaccine (Pneumococcal Disease) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 35: Global: Vaccine (Diphtheria/Tetanus/Pertussis-DPT) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 36: Global: Vaccine (Diphtheria/Tetanus/Pertussis-DPT) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 37: Global: Vaccine (Tuberculosis) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 38: Global: Vaccine (Tuberculosis) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 39: Global: Vaccine (Haemophilus Influenzae-Hib) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 40: Global: Vaccine (Haemophilus Influenzae-Hib) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 41: Global: Vaccine (Typhoid) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 42: Global: Vaccine (Typhoid) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 43: Global: Vaccine (Other Bacterial Diseases) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 44: Global: Vaccine (Other Bacterial Diseases) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 45: Global: Vaccine (Viral Diseases) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 46: Global: Vaccine (Viral Diseases) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 47: Global: Vaccine (Hepatitis) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 48: Global: Vaccine (Hepatitis) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 49: Global: Vaccine (Influenza) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 50: Global: Vaccine (Influenza) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 51: Global: Vaccine (Human Papillomavirus-HPV) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 52: Global: Vaccine (Human Papillomavirus-HPV) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 53: Global: Vaccine (Measles/Mumps/Rubella-MMR) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 54: Global: Vaccine (Measles/Mumps/Rubella-MMR) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 55: Global: Vaccine (Rotavirus) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 56: Global: Vaccine (Rotavirus) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 57: Global: Vaccine (Herpes Zoster) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 58: Global: Vaccine (Herpes Zoster) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 59: Global: Vaccine (Varicella) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 60: Global: Vaccine (Varicella) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 61: Global: Vaccine (Japanese Encephalitis) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 62: Global: Vaccine (Japanese Encephalitis) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 63: Global: Vaccine (Rubella) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 64: Global: Vaccine (Rubella) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 65: Global: Vaccine (Polio) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 66: Global: Vaccine (Polio) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 67: Global: Vaccine (Rabies) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 68: Global: Vaccine (Rabies) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 69: Global: Vaccine (Dengue) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 70: Global: Vaccine (Dengue) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 71: Global: Vaccine (Other Viral Diseases) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 72: Global: Vaccine (Other Viral Diseases) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 73: Global: Vaccine (Intramuscular and Subcutaneous Administration) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 74: Global: Vaccine (Intramuscular and Subcutaneous Administration) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 75: Global: Vaccine (Oral Administration) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 76: Global: Vaccine (Oral Administration) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 77: Global: Vaccine (Other Routes of Administration) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 78: Global: Vaccine (Other Routes of Administration) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 79: Global: Vaccine (Multivalent Vaccine) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 80: Global: Vaccine (Multivalent Vaccine) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 81: Global: Vaccine (Monovalent Vaccine) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 82: Global: Vaccine (Monovalent Vaccine) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 83: Global: Vaccine (Preventive Vaccine) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 84: Global: Vaccine (Preventive Vaccine) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 85: Global: Vaccine (Therapeutic Vaccine) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 86: Global: Vaccine (Therapeutic Vaccine) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 87: Global: Vaccine (Hospitals) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 88: Global: Vaccine (Hospitals) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 89: Global: Vaccine (Clinics) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 90: Global: Vaccine (Clinics) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 91: Global: Vaccine (Vaccination Centres) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 92: Global: Vaccine (Vaccination Centres) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 93: Global: Vaccine (Academic and Research Institutes) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 94: Global: Vaccine (Academic and Research Institutes) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 95: Global: Vaccine (Other End Users) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 96: Global: Vaccine (Other End Users) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 97: Global: Vaccine (Hospital Pharmacies) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 98: Global: Vaccine (Hospital Pharmacies) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 99: Global: Vaccine (Retail Pharmacies) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 100: Global: Vaccine (Retail Pharmacies) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 101: Global: Vaccine (Institutional Sales) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 102: Global: Vaccine (Institutional Sales) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 103: Global: Vaccine (Other Distribution Channels) Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 104: Global: Vaccine (Other Distribution Channels) Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 105: North America: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 106: North America: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 107: United States: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 108: United States: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 109: Canada: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 110: Canada: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 111: Asia Pacific: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 112: Asia Pacific: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 113: China: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 114: China: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 115: Japan: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 116: Japan: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 117: India: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 118: India: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 119: South Korea: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 120: South Korea: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 121: Australia: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 122: Australia: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 123: Others: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 124: Others: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 125: Europe: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 126: Europe: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 127: Germany: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 128: Germany: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 129: France: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 130: France: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 131: United Kingdom: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 132: United Kingdom: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 133: Italy: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 134: Italy: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 135: Spain: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 136: Spain: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 137: Russia: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 138: Russia: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 139: Others: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 140: Others: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 141: Latin America: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 142: Latin America: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 143: Brazil: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 144: Brazil: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 145: Mexico: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 146: Mexico: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 147: Others: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 148: Others: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 149: Middle East and Africa: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 150: Middle East and Africa: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 151: Turkey: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 152: Turkey: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 153: GCC Countries: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 154: GCC Countries: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 155: Israel: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 156: Israel: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 157: Others: Vaccine Market: Sales Value (in Million ?????????????????????USD), 2019 & 2024
Figure 158: Others: Vaccine Market Forecast: Sales Value (in Million ?????????????????????USD), 2025-2033
Figure 159: Global: Vaccine Industry: SWOT Analysis
Figure 160: Global: Vaccine Industry: Value Chain Analysis
Figure 161: Global: Vaccine Industry: Porters Five Forces Analysis
Table 1: Global: Vaccine Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Vaccine Market Forecast: Breakup by Technology (in Million ?????????????????????USD), 2025-2033
Table 3: Global: Vaccine Market Forecast: Breakup by Patient Type (in Million ?????????????????????USD), 2025-2033
Table 4: Global: Vaccine Market Forecast: Breakup by Indication (in Million ?????????????????????USD), 2025-2033
Table 5: Global: Vaccine Market Forecast: Breakup by Route of Administration (in Million ?????????????????????USD), 2025-2033
Table 6: Global: Vaccine Market Forecast: Breakup by Product Type (in Million ?????????????????????USD), 2025-2033
Table 7: Global: Vaccine Market Forecast: Breakup by Treatment Type (in Million ?????????????????????USD), 2025-2033
Table 8: Global: Vaccine Market Forecast: Breakup by End User (in Million ?????????????????????USD), 2025-2033
Table 9: Global: Vaccine Market Forecast: Breakup by Distribution Channel (in Million ?????????????????????USD), 2025-2033
Table 10: Global: Vaccine Market Forecast: Breakup by Region (in Million ?????????????????????USD), 2025-2033
Table 11: Global: Vaccine Market: Competitive Structure
Table 12: Global: Vaccine Market: Key Players
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security